Personalized Therapy.
Logo

Personalized Therapy

Make a calculated first move.

Interventional Oncology / Cancer Therapies & Ablation / TheraSphere / Personalized Therapy

Personalized Dosing is Linked to Optimized Results

When you can calculate each dose specifically to the needs of each patient, you’re better able to improve tumor* response and optimize outcomes. TheraSphere equips you with a dialed-in individualized dose that’s ready to use and easy to administer.

Personalized Dosimetric Approach Improves Overall Survival

Dr Salem-Impact of DOSISPHERE-01 Trial.
Riad Salem, MD, Chief of Vascular Interventional Radiology at Northwestern Medicine discusses the DOSISPHERE-01 trial.
Professor Garin-DOSISPHERE-01: An Innovative Trial Design.
Professor Etienne Garin, Principal Investigator of the DOSISPHERE-01 trial, discusses the innovative design of the trial and what makes it unique.

DOSISPHERE-01 Trial Summary

Administration of a personalized, multicompartment TheraSphere dose in the Level I prospective, randomized study, DOSISPHERE-01, showed a 26.7 month overall survival for large HCC tumor* patients.1


DOSISPHERE-01 Trial Summary Overall ITT Chart

 

Hear From Y-90 Leaders

Each patient is unique.
Hear Y-90 physicians discuss the benefits and importance of a personalized dosimetric approach.

 
Dr Salem-A Unique Infusion of Microspheres for Unique Tumors.
Riad Salem, MD an Interventional Radiologist at Northwestern Memorial Hospital talks about using TheraSphere to personalize treatment and optimize dosimetry.
 
Dr Kim-Delivering on a Promise.
Edward Kim, MD FSIR, Associate Professor of Radiology and Surgery, Director of Interventional Oncology with Mount Sinai Health Systems thinks TheraSphere allows for a predictable response and delivers reliable results. “You put a lot of planning into your treatments and you want it to be executed a hundred percent.”
 
Dr Padia-The Evolution of Dosimetry.
Siddarth Padia, MD an Interventional Radiologist with UCLA Medical Center notes a lot has changed since he started treating HCC patients. “We just did a single standard dose for every single patient,” he recalled. “With an increased understanding of dosimetry, comes significantly better outcomes.”

 

Patient Stories

Hear from physicians who recount patient experiences and the impact TheraSphere had on their lives.

 
Dr Tablri-Transforming the Odds for a Transplant Patient.
Nora Tabori, MD shares her experience helping a young transplant patient. “I’ve bridged several patients to transplant at this point that were not previously considered transplant patients.” Dr. Tabori shares the story of a young woman who wasn’t a great surgical candidate. Two years after treating her with TheraSphere she’s still doing well.
 
Dr Kim-Buying Invaluable Time.
“If it wasn't for TheraSphere, he wouldn't have enjoyed the quality of his life that he had.” Edward Kim, MD FSIR, recalls the inspiring story of an expecting father, a devastating diagnosis, and the two happy years the new dad was able to spend with his son.
Dosisphere:
  1. Garin et al, J Clin Oncol 38, 2020 (suppl 4; abstr 516)

    *Refers to HCC or associated tumors
 
Top